Literature DB >> 31780574

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Kevin J Monahan1,2, Nicola Bradshaw3, Sunil Dolwani4, Bianca Desouza5, Malcolm G Dunlop6, James E East7,8, Mohammad Ilyas9, Asha Kaur10, Fiona Lalloo11, Andrew Latchford12, Matthew D Rutter13,14, Ian Tomlinson15,16, Huw J W Thomas17,2, James Hill11.   

Abstract

Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost 30% of the population in the UK have a family history of CRC. The quantification of an individual's lifetime risk of gastrointestinal cancer may incorporate clinical and molecular data, and depends on accurate phenotypic assessment and genetic diagnosis. In turn this may facilitate targeted risk-reducing interventions, including endoscopic surveillance, preventative surgery and chemoprophylaxis, which provide opportunities for cancer prevention. This guideline is an update from the 2010 British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland (BSG/ACPGBI) guidelines for colorectal screening and surveillance in moderate and high-risk groups; however, this guideline is concerned specifically with people who have increased lifetime risk of CRC due to hereditary factors, including those with Lynch syndrome, polyposis or a family history of CRC. On this occasion we invited the UK Cancer Genetics Group (UKCGG), a subgroup within the British Society of Genetic Medicine (BSGM), as a partner to BSG and ACPGBI in the multidisciplinary guideline development process. We also invited external review through the Delphi process by members of the public as well as the steering committees of the European Hereditary Tumour Group (EHTG) and the European Society of Gastrointestinal Endoscopy (ESGE). A systematic review of 10 189 publications was undertaken to develop 67 evidence and expert opinion-based recommendations for the management of hereditary CRC risk. Ten research recommendations are also prioritised to inform clinical management of people at hereditary CRC risk. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  colorectal cancer; colorectal surgery; genetic testing; inherited cancers; surveillance

Mesh:

Substances:

Year:  2019        PMID: 31780574      PMCID: PMC7034349          DOI: 10.1136/gutjnl-2019-319915

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  283 in total

Review 1.  The risk of gastrointestinal carcinoma in familial juvenile polyposis.

Authors:  J R Howe; F A Mitros; R W Summers
Journal:  Ann Surg Oncol       Date:  1998-12       Impact factor: 5.344

2.  Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial.

Authors:  Chris Hurt; Rajeswari Ramaraj; Angela Farr; Meleri Morgan; Namor Williams; Ceri J Philips; Geraint T Williams; Georgina Gardner; Catherine Porter; Julian Sampson; Sharon Hillier; Hayley Heard; Sunil Dolwani
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-03-16

3.  Prevalence of adenomas and advanced adenomas in patients in the 40- to 49-year age group undergoing screening colonoscopy because of a family history of adenoma/polyp in a first-degree relative.

Authors:  Akshay Gupta; Jewel Samadder; Eric Elliott; Saurabh Sethi; Philip Schoenfeld
Journal:  Gastrointest Endosc       Date:  2012-04       Impact factor: 9.427

4.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

5.  Colonoscopy reduced distal colorectal cancer risk and excess cancer risk associated with family history.

Authors:  Sophie Morois; Vanessa Cottet; Antoine Racine; Françoise Clavel-Chapelon; Franck Carbonnel; Nadia Bastide; Marie-Christine Boutron-Ruault
Journal:  Cancer Causes Control       Date:  2014-07-22       Impact factor: 2.506

6.  Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome.

Authors:  K S Boparai; J B Reitsma; V Lemmens; T A M van Os; E M H Mathus-Vliegen; J J Koornstra; F M Nagengast; L P van Hest; J J Keller; E Dekker
Journal:  Gut       Date:  2010-06-28       Impact factor: 23.059

7.  A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.

Authors:  John Burn; D Timothy Bishop; Pamela D Chapman; Faye Elliott; Lucio Bertario; Malcolm G Dunlop; Diana Eccles; Anthony Ellis; D Gareth Evans; Riccardo Fodde; Eamonn R Maher; Gabriela Möslein; Hans F A Vasen; Julie Coaker; Robin K S Phillips; Steffen Bülow; John C Mathers
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

8.  Yield of screening colonoscopy in first-degree relatives of patients with serrated polyposis syndrome.

Authors:  Yark Hazewinkel; Jan-Jacob Koornstra; Karam S Boparai; Theo A M van Os; Kristien M A J Tytgat; Susanne Van Eeden; Paul Fockens; Evelien Dekker
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

9.  The association of tumor microsatellite instability phenotype with family history of colorectal cancer.

Authors:  Bharati Bapat; Noralane M Lindor; John Baron; Kim Siegmund; Lin Li; Yingye Zheng; Robert Haile; Steve Gallinger; Jeremy R Jass; Joanne P Young; Michelle Cotterchio; Mark Jenkins; John Grove; Graham Casey; Stephen N Thibodeau; D Timothy Bishop; John L Hopper; Dennis Ahnen; Polly A Newcomb; Loic Le Marchand; John D Potter; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

10.  Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer.

Authors:  L I H Overbeek; C M Kets; K M Hebeda; D Bodmer; E van der Looij; R Willems; M Goossens; N Arts; H G Brunner; J H J M van Krieken; N Hoogerbrugge; M J L Ligtenberg
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

View more
  61 in total

1.  Serrated adenomas with a BRAF mutation in a young patient with familial adenomatous polyposis.

Authors:  Kentaro Moriichi; Hiroki Tanabe; Yusuke Ono; Yu Kobayashi; Yuki Murakami; Takuya Iwama; Takehito Kunogi; Takahiro Sasaki; Keitaro Takahashi; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Hidehiro Takei; Yusuke Mizukami; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Int J Colorectal Dis       Date:  2020-06-05       Impact factor: 2.571

Review 2.  Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients.

Authors:  Mingzhu Sun; Jayne Moquet; Michele Ellender; Simon Bouffler; Christophe Badie; Rachel Baldwin-Cleland; Kevin Monahan; Andrew Latchford; David Lloyd; Susan Clark; Nicola A Anyamene; Elizabeth Ainsbury; David Burling
Journal:  Fam Cancer       Date:  2022-06-20       Impact factor: 2.375

Review 3.  MUTYH-associated tumor syndrome: The other face of MAP.

Authors:  Luigi Magrin; Daniele Fanale; Chiara Brando; Lidia Rita Corsini; Ugo Randazzo; Marianna Di Piazza; Vittorio Gurrera; Erika Pedone; Tancredi Didier Bazan Russo; Salvatore Vieni; Gianni Pantuso; Antonio Russo; Viviana Bazan
Journal:  Oncogene       Date:  2022-04-14       Impact factor: 9.867

4.  Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology.

Authors:  Rosie O'Shea; Nicole M Rankin; Maira Kentwell; Margaret Gleeson; Katherine M Tucker; Heather Hampel; Natalie Taylor; Sarah Lewis
Journal:  Eur J Hum Genet       Date:  2021-04-02       Impact factor: 4.246

Review 5.  Progress Report: New insights into the prevention of CRC by colonoscopic surveillance in Lynch syndrome.

Authors:  Hans F A Vasen
Journal:  Fam Cancer       Date:  2021-01-19       Impact factor: 2.375

Review 6.  Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations.

Authors:  Alessandro Vanoli; Federica Grillo; Daniela Furlan; Giovanni Arpa; Oneda Grami; Camilla Guerini; Roberta Riboni; Luca Mastracci; Antonio Di Sabatino
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

7.  Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives.

Authors:  Sarah Bennett; Elizabeth Alexander; Harry Fraser; Naomi Bowers; Andrew Wallace; Emma R Woodward; Fiona Lalloo; Anne Marie Quinn; Shuwen Huang; Helene Schlecht; D Gareth Evans
Journal:  Eur J Hum Genet       Date:  2021-03-02       Impact factor: 5.351

8.  The contribution of Lynch syndrome to early onset malignancy in Ireland.

Authors:  Alice Talbot; Emily O'Donovan; Eileen Berkley; Carmel Nolan; Roisin Clarke; David Gallagher
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

9.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

10.  Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study.

Authors:  Xinrong Zhang; Vincent Wai-Sun Wong; Terry Cheuk-Fung Yip; Yee-Kit Tse; Lilian Yan Liang; Vicki Wing-Ki Hui; Guan-Lin Li; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Hepatol Commun       Date:  2021-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.